Baseline levels of CTX-MMP, TRACP5b, CTX, RANKL, osteocalcin, and PINP were dependent on whether the patients received concomitant BST as reported previously in prostate cancer patients with bone metastatic disease [38–40]. This evidence concerns the gene TNFSF11 and prostate cancer.